The Peptide Decade Will Reshape Pharmacy
It's getting noisy over here. Diary of a CEO ran a 90-minute peptide episode that went viral. HHS reversed the FDA ban on most of the restricted peptide list. The wellness industry began its pivot years ago. Your CFO's group chat is asking what BPC-157 is.
That's just one piece of the peptide equation though.
This piece is not about whether to cover Wegovy. That discussion was for last year. Let's focus on what happens next.
What the industry is still arguing about
Walk into any benefits committee meeting in 2026 and the GLP-1 conversation sounds the same. Cover or exclude. Prior auth gates. BMI thresholds. Weight-loss carveouts. Rebate math. The diabetes-only formulary trick. CVS pulling Zepbound off its template formulary set off another round of the same debate.
Mercer's 2026 survey shows 77% of large employers rank managing GLP-1 cost as extremely or very important. Translation: every CFO in the country is staring at a $400 to $700 net PMPM for GLP-1 utilizers and trying to bring it down with the tools they already have.
What is actually about to happen
The peptide category is the most-funded therapeutic platform in modern pharma history. The protein and peptide therapeutics market is forecast to move from roughly $423B in 2024 to over $712B by 2030. More than 280 peptide drugs are in preclinical or clinical evaluation. Oncology peptides are projected to compound at 16%+ CAGR through the early 2030s.
You already know about the obesity and diabetes pipeline. What is not yet priced into most plans:
- Peptide-drug conjugates in oncology hitting Phase 2 and 3 readouts annually through 2028.
- Long-acting peptide therapies for autoimmune disease entering late-stage trials. Takeda is leading. Amgen has its own conjugate program.
- Antimicrobial peptides positioning for the post-antibiotic era.
- Regenerative and tissue-repair peptides moving from the gray market into the FDA Pharmacy Compounding Advisory Committee's official review on July 23-24, 2026.
The HHS reversal reopened the legal pathway for licensed compounding pharmacies on most of the restricted list, which applies to anyone buying BPC-157, TB-500, GHK-Cu, and others through telehealth clinics and longevity "research" practices today.
The challenge for most plans
Pharmacy plan architecture in most mid-market groups was designed around three assumptions: drugs arrive in waves you can see a year out, formulary review is an annual exercise, and stop-loss can be priced against a stable specialty curve.
All three assumptions are now wrong.
PBM contracts are static. Most three-year PBM contracts signed in 2024 were written before retatrutide, MariTide, CagriSema, orforglipron, and survodutide had Phase 3 readouts. Your rebate guarantees, your exclusion clauses, and your specialty definitions were drafted for a pipeline 30% smaller than what is actually launching.
Stop-loss is not priced for sustained expansion. Plans covering obesity indications are running 15% to 25% pharmacy trend right now. Each new indication (sleep apnea, MASH, cardiovascular event reduction, kidney, addiction medicine) enlarges the eligible population without a new molecule. Your laser strategy, your aggregating spec, and your renewal model probably assume the curve flattens. It does not flatten when six new molecules with overlapping indications arrive in 24 months.
Formulary review cadence is wrong. P&T committees that meet quarterly cannot keep pace with monthly pipeline news, indication expansions, and biosimilar entry signals. By the time your formulary committee debates a peptide, the manufacturer has announced two more indications.
Outcome infrastructure does not exist. Almost no mid-market plan has the data plumbing to tie peptide coverage to measurable outcomes: weight maintained at 12 months, A1c sustained, cardiovascular event reduction, treatment adherence. Without that infrastructure, every coverage decision is a faith bet rather than an architecture decision.
What a peptide-era plan actually looks like
Here is the architecture shift. Five moves to make in the next 12 months.
- Rewrite PBM contract language. Add peptide-specific clauses: indication-tier flexibility, biosimilar trigger pricing, manufacturer rebate floors tied to label expansion, and the right to carve out a single therapeutic class.
- Recalibrate stop-loss. Push your carrier for laser flexibility on peptide claimants and model your aggregating spec against a 25% pharmacy trend scenario, not the 8% to 12% historical specialty number.
- Move formulary review to a continuous cadence. Replace the quarterly meeting with a rolling review triggered by FDA decision dates, label expansions, and biosimilar filings. Build the calendar against the published pipeline, not against your renewal cycle.
- Tie coverage to outcomes, not enrollment. Build value-based triggers: continued coverage contingent on documented adherence, weight maintenance, or A1c control at 6 and 12 months. Most great PBMs are doing this.
- Build employee education for the gray market. Compounded peptides bought through telehealth are not going away. Plan documents should address them. Wellness programs should educate on safety, FDA status, and interaction risk. Silence is a liability position.
These five tips should help you navigate the upcoming peptide decade.
The provocation
Most peptide commentary in our industry right now is descriptive. It tells you what is coming. It does not tell you what to change.
That is because the dominant business model in benefits brokerage rewards stability: renewal cycles, annual strategy decks, quarterly stewardship reports. The plans that win in the upcoming decade, are going to be the plans whose architecture is built for continuous adaptation.
For a deeper drug-by-drug breakdown of the molecules driving the pipeline through 2030, see the companion piece on Benefits Blake.
The bottom line
The peptide decade is not a coverage problem. It is an architecture problem. The actual work is in your contract language, your stop-loss model, your formulary review cadence, your outcome measurement, and your employee education infrastructure.
Build for that and you will spend the next five years pulling cost out of a category that is about to swell.
If you want this analysis in your inbox as the pipeline moves (and it will move fast), subscribe to the DSP blog.